Desk note · industry · Pharma / biotech
On 15 October 2026 Mankind Pharma agreed to acquire 70% of Belgium’s Armed Cell Therapeutics for €48 million through its Netherlands subsidiary, gaining experimental CAR-T programmes in blood and lung cancers.
On 15 October 2026, Mankind Pharma Ltd signed a definitive agreement to take a 70% stake in Armed Cell Therapeutics, a biotechnology company based in Belgium. The price is €48 million, to be invested through its Dutch subsidiary Mankind Pharma (Netherlands) B.V. ACTx researches chimeric antigen receptor T-cell therapies, which reprogramme a patient’s immune cells to attack cancer. Its pipeline includes programmes aimed at non-Hodgkin lymphoma and small cell lung cancer, diseases where standard options can run out quickly. Mankind’s earlier deals, including the 2024 acquisition of Bharat Serums and Vaccines, focused on marketed and near-market assets in India. This transaction is a bet on early science abroad.
CAR-T treatments have shown strong results in some blood cancers but remain expensive and complex to manufacture. Indian patients rarely access the latest cell therapies at scale because trials, plants, and payers sit overseas. Owning a platform company gives Mankind a seat at the lab bench rather than waiting for licensing talks years later. The science is still experimental. Regulators in Europe and India will want years of safety data before any therapy reaches hospitals. Mankind exports about 15% of revenue to Europe today, so the firm already knows those markets, yet R&D spend will rise before any product sales follow.
If you follow Indian pharma, compare this deal with peers who license oncology drugs instead of buying labs. Hospital chains and insurers should track whether any ACTx candidate eventually seeks trials in India, which could change high-cost cancer budgets. Employees and suppliers see management tilting capital toward innovation, not just branded generics. Watch closing conditions, how much extra EUR 50 million the board allowed for follow-on funding, and whether Mankind partners with a hospital chain for future clinical work.
Trade policy / exports
Commerce minister Piyush Goyal said on 22 October 2026 that India’s proposed free-trade agreement with the European Union could become operational within four to five months after signing, with the deal expected to be inked before year-end during his visit to Germany.
Food delivery / quick commerce
Swiggy reported on 22 October 2026 that September-quarter revenue rose 36% to about ₹7,571 crore and the consolidated net loss narrowed to ₹922 crore, as food delivery posted record adjusted core profit of about ₹349 crore while quick-commerce Instamart lost about ₹764 crore at the segment level amid heavier discounting and 69 new dark stores.
Quick-service restaurants / consumers
KFC and Pizza Hut operator Sapphire Foods India said on 22 October 2026 that September-quarter consolidated restaurant sales rose 20% year on year to about ₹885 crore, with KFC India same-store sales up 14% and adjusted EBITDA margin expanding 100 basis points to 7.1% even as the listed stock remained far below its 52-week high.
RBI / government borrowing
On 22 October 2026, the Reserve Bank of India accepted no bids at the scheduled sale of short-dated government treasury bills, the first full cancellation in about seven months, as investors demanded higher yields amid a bond selloff, oil-linked inflation fears, and expectations of more rate hikes after October’s policy minutes.
For informational purposes only. Not investment advice. Verify with filings and a licensed adviser.